Evidence map›Paper›PMID 40985275›Full record

ReviewJournal of cellular physiology2025

Mitochondrial Ca

Jillian S Weissenrieder, J Kevin Foskett

Abstract readReview
In one paragraph

Review in Journal of cellular physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Mitochondrial Metabolism and Dynamics in Cancer Cells.Cancer treatment and research · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jillian S WeissenriederDepartment of Physiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-8096-5421
J Kevin FoskettDepartment of Physiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Funding

Endoplasmic Reticulum-to-Mitochondria Calcium Transfer in Pancreatic Cancer Development, Metastasis, and TreatmentR01CA250173 · NCI · UNIVERSITY OF PENNSYLVANIA · PI FOSKETT, JAMES KEVIN · 2021 to 2025
$2.6M
The Mitochondrial Calcium Uniporter in Pancreatic Cancer Development, Metastasis, and TreatmentF32CA250144 · NCI · UNIVERSITY OF PENNSYLVANIA · PI WEISSENRIEDER, JILLIAN · 2021 to 2023
$205k
NCI NIH HHS F32 CA250144NCI NIH HHS R01 CA250173
6 · The paper itself

Abstract

Cancer is a leading cause of death in developed countries, despite many breakthroughs in targeted small molecule and immunotherapeutic interventions. A deeper understanding of the characteristics and processes that underlie malignancy will enable us to develop more effective therapeutic options to improve patient outcomes. One particular area of interest is in cancer cell metabolism. Even as early as the 1920s, Otto Warburg recognized dysregulated metabolism in cancerous cells. Altered metabolism may provide targetable nutrient dependencies for further clinical development, either by nutrient restriction or pathway inhibition. More recently, researchers have observed an increasingly strong linkage between altered mitochondrial Ca

Indexed as

CalciumCalcium SignalingEnergy MetabolismMitochondriaNeoplasmsAnimalsCell ProliferationHomeostasisHumansCalciumCa2+ signalingcancermetabolismmitochondria

Identifiers

PMID40985275
PMCPMC12455693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.